Former Premier of Quebec Pierre Marc Johnson joins Medicago's

Board of Directors 
QUEBEC CITY, Oct. 19 /CNW/ - Medicago Inc. (TSX-V: MDG), a biotechnology 
company focused on developing highly effective and affordable vaccines based on 
proprietary manufacturing technologies and Virus-Like Particles (VLPs), today 
announced the appointment of Mr. Pierre Marc Johnson, attorney, physician and 
former Premier of Quebec, to its Board of Directors. Mr. Johnson replaces Mr. 
Damien Levesque, who is leaving the Board of Medicago after serving for nine 
years. Mr. Levesque will continue to assist Medicago as a Consultant. 
"We are pleased to welcome Mr. Johnson to Medicago's Board," said Dr. Randal 
Chase, Chairman of the Medicago Board of Directors. "As one of Quebec's 
prominent leaders, Mr. Johnson brings a wealth of strategic insight and solid 
experience working in governments and businesses. His knowledge of public 
policy and regulatory processes as well as business activities will make of Mr. 
Johnson a great asset to Medicago in the future development and 
commercialization of its novel influenza vaccines." 
"On behalf of the Board, I would like to thank Mr. Levesque for his great 
dedication and loyal service to Medicago since the inception of the Company. 
His guidance was of great assistance to the development of our business," 
concluded Dr. Chase. 
Mr. Johnson is a lawyer, physician, former Premier of Quebec and former 
professor of law at McGill University. He has been Of Counsel with the offices 
of Heenan Blaikie LLP since 1996. He is recognized for his expertise in 
international trade negotiations and international partnerships as well as 
environmental and health law. From 1976 to 1987, he was a member of the Quebec 
Legislature Assembly and in senior cabinet positions before becoming Premier in 
1985. He was a founding Vice-Chair of the Prime Minister's National Round Table 
on the Environment and the Economy of Canada, chaired its Foreign Policy 
committee for seven years. He also served as a Special Advisor to the Secretary 
General of the United Nations Conference on Environment and Development (UNCED) 
and to the North American Commission on Environmental Cooperation. Mr. Johnson 
was a director of several major corporations and currently sits on the boards 
of ACE Aviation Holdings Corporation, Air Canada and Holcim Canada; he chairs 
the foresight committee of the Veolia Institute for the Environment of Paris. 
In 2006, he was appointed chair of the board of directors of the Quartier de la 
Santé (Health district corporation), a Montreal-based organization created to 
foster diagnostic and therapeutic innovation. Mr. Johnson holds an honorary 
doctorate from the Université Claude Bernard Lyon I, France. He is Fellow of 
the Royal Society of Canada, Grand Officier of the Ordre de la Pléiade and 
Grand Officer of the Ordre National du Québec. 
Concurrently with his appointment, Mr. Johnson was granted 37,500 options at an 
exercise price of $0.60. Said options are governed by the stock options plan of 
the Company and will vest in three yearly installments. 
About Medicago 
Medicago is committed to provide highly effective and affordable vaccines based 
on proprietary Virus-Like Particle (VLP) and manufacturing technologies. 
Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, 
using a transient expression system which produces recombinant vaccine antigens 
in non-transgenic plants. This technology has potential to offer advantages of 
speed and cost over competitive technologies. It could deliver a vaccine for 
testing in about a month after the identification and reception of genetic 
sequences from a pandemic strain. This production time frame has the potential 
to allow vaccination of the population before the first wave of a pandemic 
strikes and to supply large volumes of vaccine antigens to the world market. 
Additional information about Medicago is available at 
Forward Looking Statements 
This press release contains forward-looking statements which reflect Medicago's 
current expectations regarding future events. The forward-looking statements 
involve risks and uncertainties. Actual results could differ materially from 
those projected herein. Medicago disclaims any obligation to update these 
forward-looking statements. 

    Neither TSX Venture Exchange nor its Regulation Services Provider (as
    that term is defined in the policies of the TSX Venture Exchange) accepts
    responsibility for the adequacy or accuracy of this release
    %SEDAR: 00023641EF

For further information: Medicago, Inc., Andy Sheldon, President and CEO, (418) 
658-9393; Medicago Inc., Arianna Vanin, Director, Investor Relations, (514) 796-

CO: Medicago Inc.
ST: Quebec
-0- Oct/19/2009 12:30 GMT

Press spacebar to pause and continue. Press esc to stop.